KRYS · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
XNAS · KRYS
+0.31% · +$1.01 · Vol 324.5K
After hours · updated 16:51:30 ET
Krystal Biotech, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$325.78
Veridion Score
BETAHIGH CONF · 6/6 factorsStale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · KRYS
MethodologyKRYS
Krystal Biotech, Inc. Common Stock
Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is KRYS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Krystal Biotech, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2017
Employees
295
Country
US
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$326.86
Day high
$331.07
Day low
$316.15
Previous close
$324.77
52W high
$378.15
-13.85% from high
52W low
$136.00
78% of range
Market cap
$9.6B
P/E
43.04×
EPS
$7.57
Beta
0.38
Shares out
29.6M
Volume
324.5K
0.57× rel vol
Avg volume
569K
VWAP
$323.22
Price history computed in-house
1W
-10.32%
1M
-13.05%
3M
+9.80%
1Y
+137.19%
YTD
+32.14%
SMA 50 $338.51 · below
SMA 200 $273.93 · above
52W position 78%
KRYS overview
Veridion Score
59
6 of 6 factors measured
Congress receipts
1
Christopher L. Jacobs · Purchase
13F holders
None on file
Related filings and maps
Public disclosures
Congress activity in KRYS
Official filing ↗
Federal contracts
KRYS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KRYS in this window.
Lobbying spend
KRYS lobbying filings, year to date.
Registered lobbying filings matched to Krystal Biotech, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KRYS in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for KRYS.
Options
Sovereign unlock shows live options positioning for KRYS.